John Bell

John Irving Bell is the founder of The Wellcome Trust Centre for Human Genetics, founded in 1993.
Dr. Bell was the founder of Oxagen Ltd., founded in 1997, and served as Non-Executive Director from 1997 to 2017.
Dr. Bell is also the founder of Powderject Pharmaceuticals Plc,Avidex Ltd...
Dr. Bell is currently Co-Chief Executive Officer at Ellison Institute of Technology since 2024.
Dr. Bell is Chairman-Partnership Board at Oxford Centre for Diabetes Endocrinology & Metabolism since 1999.
Dr. Bell is Chairman at The Oxford Health Alliance, GMEC Management Co. Ltd., Office for Strategic Co-ordination of Health Research, and Immunocore Holdings Plc since 2015.
Dr. Bell is Non-Executive Director at The Jenner Institute Laboratories since 2013, Oxford University Hospitals NHS Trust, The Gray Laboratory Cancer Research Trust, Genomics England Ltd., and Oxford Science Enterprises PLC.
Dr. Bell is Trustee at Rhodes Trust, The Ewelme Almshouse Charity, and Our Future Health Uk.
Dr. Bell is Advisor at Biospring Management Partners LP.
Former jobs include Chairman at Arcturis Data Ltd., Director at Genentech, Inc. and Atopix Therapeutics Ltd., Non-Executive Director at Roche Holding AG from 2011 to 2020, and at F.
Hoffmann-La Roche Ltd. Dr. Bell was President of the Academy of Medical Sciences from 2006 to 2011.
Dr. Bell was Professor at the University of Oxford from 2002 to 2024.
Education includes a doctorate conferred in 1990 and an undergraduate degree conferred in 1979 from Magdalen College School Oxford Ltd, and an undergraduate degree conferred in 1975 from the University of Alberta.